Brief: Scribe Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
02/09/2026 21:31
BRIEF-Scribe Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights Sept 2 (Reuters) - Scribe Therapeutics Inc SCTX.O:
SCRIBE THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS
SCRIBE THERAPEUTICS - Q2 2026 COLLABORATION REVENUE $1.90 MILLION VERSUS $4.90 MILLION IN Q2 2025
SCRIBE THERAPEUTICS - Q2 2026 NET LOSS $6.50 MILLION OR $2.62 PER SHARE VERSUS $9.90 MILLION OR $4.08 PER SHARE IN Q2 2025
Source text: ID:nGNX3vyDph
Further company coverage: SCTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scribe Therapeutics
See all newsBrief: Scribe Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Scribe Therapeutics surges in New York debut after upsized $128.7 million IPO
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor
NASDAQ RESUMED AT 11:50 AM